Frontlight ResearchEarly access
CompletedNo phase
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
Key facts
- Who runs it
- Alcon Research
- Where
- Houston, Kansas City, Mt. Pleasant, Salt Lake City, and Torrance, United StatesSee the 5 sites
- Trial code
- Status
- Completed
- People taking part
- 110 people enrolled
- Started
- 14 Oct 2025
- Ended
- 7 Oct 2026
- Type of study
- Interventional
- Treatments tested
- Clareon PanOptix Pro/Pro Toric Trifocal IOL
- Phacoemulsification
- Record updated
- 19 October 2026
Who can take part
- Age
- 22 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Subjects with cataracts in both eyes, planned for removal by routine surgery (phacoemulsification)
- Subject must be able to understand and sign an approved informed consent form
- Subject is willing to complete all the required study visits for the duration of the study
- Other protocol-defined inclusion criteria may apply
Who cannot take part
- Previous intraocular or corneal surgery
- Ocular conditions as specified in the protocol
- Subjects who desire monovision correction
- Other protocol-defined exclusion criteria may apply
Where in United States
- Houston Eye AssociatesHouston, United States
- Moyes Eye CenterKansas City, United States
- Carolina Eyecare Physicians LLCMt. Pleasant, United States
- The Eye Institute of UtahSalt Lake City, United States
- Wolstan & Goldberg Eye AssociatesTorrance, United States
About the trial
What the trial wants to find out
The purpose of this study is to collect safety and performance data on two approved intraocular lenses (IOLs). This study will be conducted in participants who require cataract surgery in both eyes. The IOLs are designed to provide vision at far, arm's length, and near.
The group in the trial
- Clareon PanOptix Pro/Pro Toric Trifocal IOLTreatment being tested
The clouded lens will be removed by phacoemulsification, after which the PanOptix Pro and/or PanOptix Pro Toric IOLs will be implanted.
Treatment: Clareon PanOptix Pro/Pro Toric Trifocal IOL and Phacoemulsification
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 19 October 2026